目的 探讨抗痨丸联合莫西沙星治疗肺结核的临床疗效。方法 选取2015年3月-2016年3月在郑州市第六人民医院进行治疗的肺结核患者96例，根据治疗方案的差别分为对照组（48例）和治疗组（48例）。对照组口服盐酸莫西沙星片，1片/次，1次/d。治疗组在对照组的基础上口服抗痨丸，1丸/次，3次/d。两组患者均连续治疗6个月。比较两组患者治疗前后临床疗效、痰菌转阴率和血清学指标。结果 治疗后，对照组和治疗组的总有效率分别为81.25%和97.92%，两组总有效率比较差异有统计学意义（P<0.05）。治疗后，对照组痰菌转阴率为81.25%，显著低于治疗组的97.92%，两组比较差异有统计学意义（P<0.05）。治疗后，两组患者血清C-反应蛋白（CRP）、白细胞介素-10（IL-10）、肿瘤坏死因子-α（TNF-α）及降钙素原（PCT）水平均显著降低，同组治疗前后比较差异具有统计学意义（P<0.05）；且治疗组上述指标降低水平优于对照组，两组比较差异具有统计学意义（P<0.05）。结论 抗痨丸联合莫西沙星治疗肺结核效果显著，可明显改善机体炎性因子水平，具有一定的临床推广应用价值。

Objective To explore the clinical efficacy of Kanglao Pills combined with moxifloxacin in treatment of pulmonary tuberculosis. Methods Patients (96 cases) with pulmonary tuberculosis in the Sixth People's Hospital of Zhengzhou from March 2015 to March 2016 were divided into control (48 cases) and treatment (48 cases) groups based on different treatments. Patients in the control group were po administered with Moxifloxacin Hydrochloride Tablets, 1 tablet/time, once daily. Patients in the treatment group were po administered with Kanglao Pills on the basis of the control group, 1 pill/time, three times daily. Patients in two groups were treated for 6 months. After treatment, the clinical efficacy, sputum negative rate, and serological indexes in two groups before and after treatment were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 81.25% and 97.92%, respectively, and there was difference between two groups (P<0.05). After treatment, the sputum negative rate in the control was 81.25%, which was significantly lower than 97.92% in the treatment group, with significant difference between two groups (P<0.05). After treatment, CRP, IL-10, NF-α, and PCT in two groups was significantly decreased, and the difference was statistically significant in the same group (P<0.05). And these indicators in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). Conclusion Kanglao Pills combined with moxifloxacin has a significant effect in treatment of pulmonary tuberculosis, can significantly improve the inflammatory factors level, which has a certain clinical application value.